ACTG A5409(RAD-TB):针对肺结核治疗新型方案的2期随机、适应性、剂量探索、开放标签试验的研究方案
RAD-TB平台试验第1波(ACTG A5409,NCT06192160)将成人药物敏感肺结核初始治疗者随机分为标准治疗组(HRZE,第1组)或五个试验组之一,试验组以贝达喹啉和普托马尼为骨架(BPa)联合三种噁唑烷酮类药物之一,强化期8周,主要比较前6周痰培养阳性时间斜率及前8周新发3级或以上不良事件。
要点
- 第1波试验组为BPa联合利奈唑胺(BPaL)600 mg每日、TBI-223 1200 mg或2400 mg每日、sutezolid 800 mg或1600 mg每日。
- 主要疗效指标为前6周痰培养阳性时间斜率,主要安全性指标为前8周新发3级或以上不良事件。
- 强化期后所有参与者接受标准异烟肼和利福平(HR)继续期18周,结核治疗启动后随访52周。
核心结论
- 第1波RAD-TB平台旨在确定与BPa骨架联合用于药物敏感肺结核治疗时疗效和安全性最佳的噁唑烷酮类药物。
研究设计与样本
- RAD-TB平台试验第1波为2期随机、适应性、剂量探索、开放标签试验(ACTG A5409,NCT06192160),于2024年1月5日注册。
- 研究对象为启动药物敏感肺结核治疗的成人参与者,随机分配至标准治疗组(HRZE,第1组)或五个试验组之一,强化期8周。
主要发现
- 试验组方案为贝达喹啉和普托马尼骨架(BPa)联合一种噁唑烷酮类:第2组为利奈唑胺(BPaL)600 mg每日,第3A和3B组分别为TBI-223 1200 mg和2400 mg每日,第4A和4B组分别为sutezolid 800 mg和1600 mg每日。
- 主要疗效目标为比较每个试验组与标准治疗组在前6周治疗中痰培养阳性时间(TTP)斜率。
- 主要安全性目标为比较每个试验组与标准治疗组在前8周治疗中新发3级或以上不良事件。
- 强化期后所有参与者接受标准异烟肼和利福平(HR)继续期18周,并在结核治疗启动后随访52周以评估长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The standard of care (SOC) treatment for drug-susceptible pulmonary tuberculosis (DS-TB) consists of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE). New treatment regimen options for DS-TB are needed as HRZE is long in duration (6 months), associated with frequent adverse events, unforgiving of adherence lapses, and complicated by rifamycin-based drug-drug interactions. The recent resurgence of TB drug development, particularly in the context of drug-resistant TB, offers promise for additional regimens for persons with DS-TB, provided they are sufficiently effective and well-tolerated. We spotlight wave 1 of the RAD-TB platform trial (ACTG A5409, NCT06192160) that will investigate new chemical entities for the treatment of DS-TB. METHODS: In wave 1 of the RAD-TB platform, adult participants initiating treatment for DS-TB will be randomized to SOC (HRZE, Arm 1) or one of five experimental arms for the 8-week intensive phase. The experimental treatment arms will consist of a bedaquiline and pretomanid backbone (BPa) in combination with one of three oxazolidinones. Arm 2 will study linezolid (BPaL) at a dose of 600 mg daily, Arms 3A and 3B will study TBI-223 at 1200 mg and 2400 mg daily, respectively, and Arms 4A and 4B will study sutezolid at 800 mg and 1600 mg daily, respectively. The primary efficacy objective is to compare sputum culture time to positivity (TTP) slope over the first 6 weeks of treatment for each experimental treatment arm to SOC. The primary safety objective is to compare new Grade 3 or higher adverse events over the first 8 weeks of treatment for each experimental treatment arm to SOC. After the intensive phase, all participants will receive the standard isoniazid and rifampicin (HR) continuation phase for 18 weeks. Participants will be followed for 52 weeks after TB treatment initiation to assess long-term outcomes. DISCUSSION: Wave 1 of the RAD-TB platform aims to identify the optimal oxazolidinone(s), with regard to both efficacy and safety, to combine with the BPa backbone for the treatment of DS-TB. Subsequent waves of this platform trial may add a fourth drug to the regimen, study new diarylquinolines to substitute for bedaquiline, or study novel agents from other TB drug classes. TRIALS REGISTRATION: ClinicalTrials.gov NCT06192160 . Registered on January 5, 2024.
引用
- Harrison LJ, Velásquez GE, Kempker RR, et al. ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis. Trials. 2025. PMID: 40817073. doi:10.1186/s13063-025-08973-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。